{"date": "2021-09-09 04:38:11.684000+00:00", "ticker": "III", "mrkt_info": {"open": 1330.5, "close": 1308.0}, "html": "<div class=\"storyContent\" lang=\"fr\"><style type=\"text/css\">.storyContent * {border-color:inherit !important;outline-color:inherit !important;}</style><div class=\"tr-npp-lead\">\n<p>Bresso (awp) - Newron a annonc\u00e9 le changement suivant au sein de son actionnariat, conform\u00e9ment au r\u00e8glement de la Bourse suisse (date de publication: 09.09.2021):</p>\n<p>awp-robot</p>\n</div>\n<div class=\"tr-npp-body\">\n<pre>actionnaire                   participation   naissance de    participation   \n                                   actuelle   l'obligation     ant\u00e9rieure    \n\nEuropean Investment Bank, Lux       3,68%      06.09.2021         -  \nmotif: \u00e9mission de bons de souscription\n\nannonces pr\u00e9c\u00e9dentes:\n\nAviva Plc, UK                       2,77%      10.08.2020      \nAviva Plc, UK                       3,79%      04.08.2020       \nAviva Plc, UK                       4,78%      09.06.2020\nAviva Plc, UK                       6,16%      20.05.2020 \nInvestor AB (Duba)                  1,414%     07.05.2020\nInvestor AB (Duba)                  3,013%     06.05.2020\nAXA Investment Managers               &lt;3%      04.05.2020            \nAviva Plc, UK                       6,36%      12.03.2020      \nAviva Plc, UK                       6,36%      12.03.2020      \nNewron Pharmaceuticals S.p.A.\n- positions de vente               10,66%      25.11.2019\nPolar Capital                       2,96%      11.07.2019 \nAXA Investment Managers             3,28%      19.11.2018 \nPolar Capital                       3,08%      13.09.2018\nZambon/GEFIM, Italy                 4,41%      03.10.2017  \nAviva Plc, UK                       7,84%      01.10.2017\nInvestor AB (Duba)                  9,37%      03.10.2017\nNewron Gesch\u00e4ftsleitung/VR          3,8%       25.09.2017\nAviva Plc, UK                       7,84%      06.02.2017\nNewron Gesch\u00e4ftsleitung/VR          3,64%      12.10.2016\nNewron Pharmaceuticals S.p.A.\n- positions de vente                5,99%      28.02.2014\nAviva Plc, UK                       9,06%      28.04.2016\nZambon/GEFIM, Italy                 9,23%      21.01.2016\nInvestor AB (Duba)                 12,47%      21.01.2016\nInvestor AB (Duba/Zambon)            &lt;3%       21.01.2016\nInvestor AB (Duba/Zambon)          22,03%      02.11.2015\nJP Morgan Chase, US                 2,925%     28.09.2015\nJP Morgan Chase, US                 3,052%     24.07.2015\nJP Morgan Chase, US                 2,965%     07.11.2014\ngroupe GEFIM/Investor              24,19%      29.04.2014\nJP Morgan Chase, US                 4,697%     29.04.2014\nJP Morgan Chase, US                 5,166%     09.04.2014\ngroupe GEFIM/Investor              25,84%      20.12.2013\nHealthCap Holdings                   &lt;3%       03.10.2013\n3i Group PLC, UK                     &lt;3%       05.07.2013\nAviva Plc, UK                       6,092%     20.06.2013\nHealthCap Holdings                  4,85%      19.06.2013\nAviva Plc, UK                       4,754%     01.05.2013\nInvestor/Duba AB                   13,35%      17.04.2013\ngroupe Investor/HealthCap           5,75%      17.04.2013\ngroupe Investor/HealthCap          19,96%      08.03.2013\nOmega Fund IV, Boston               2,96%      30.01.2013\ngroupe Investor/Zambon (GEFIM)     25,63%      21.01.2013\ngroupe Investor AG/\nHealthCap Holdings, Schweden       20,64%      17.12.2012\ngroupe autour Zambon               15,9%       24.09.2012\ngroupe autour Zambon               16,1%       19.09.2012\nAviva Investors                     6,76%      20.08.2012\nOmega Fund IV, Boston               4,72%      20.08.2012\nZambon Company Spa                12,36%       23.07.2012\nGreat Point Partners, US           &lt;3%         k.A. \nFCRP APAX/ALTAMIR AMBOISE, F        2,7%       18.05.2012\nFCRP APAX/ALTAMIR AMBOISE, F        4,36%      14.05.2012\nZambon Company Spa                9,99996%     11.04.2012\nNWB Investissements SPRL           &lt;3%         23.03.2012\nFCRP APAX FRANCE VI / \nALTAMIR AMBOISE                     5,66%      23.03.2012\nGoodman &amp; Company, Canada           &lt;3%        30.11.2011\nGoodman &amp; Company, Canada           9,92%         k.A.  \nCapital Group Companies Inc.        2,3127%     13.01.2011\nGreat Point Partners, US            9,1%       07.01.2011\nT. Rowe Price, US                   2,96%      30.12.2010\nT. Rowe Price                       4,95%      09.09.2010\nGoodman Company                    10,8%       25.01.2010\nAviva                               3,584%     25.01.2010\n3i Group PLC, UK                    8,23%      25.01.2010\nT. Rowe Price                       7,68%      20.11.2009\nCapital Group Companies Inc.        6,08%      20.11.2009\nHBM BioVentures                     2,98%      16.11.2009\nHBM BioCapital                      2,96%      11.11.2009\nNPI Services S.a.r.l.               &lt;3%        26.08.2009\nGoodman Company                    10,04%      21.08.2009\nHBM BioVentures                     4,99%      24.06.2009\nHBM BioCapital                      4,92%      20.05.2009</pre>\n</div><p class=\"line-break\"><br/></p><p class=\"tr-copyright\">Copyright (c) 2021 Thomson Reuters Limited.</p></div>"}